Clinical trial
Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small…
NCT00387322 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00387322 |
|---|---|
| Title | Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors |
| Official title | Phase I/II Study of Two Different Schedules of Pemetrexed (ALIMTA) and Erlotinib (TARCEVA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride, pemetrexed disodium |
| Enrollment | 42 |
| Start date | Mar 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | May 1, 2009 |
| First posted | Oct 13, 2006 |
| Last update posted | Mar 29, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: